Latest News
AZZ (NYSE:AZZ) outlined its growth strategy, updated financial outlook and acquisition priorities during a Sidoti investor presentation, highlighting demand from infrastructure, electrification, reshoring and selected data-center projects.
Dave Nark, AZZ’s chief marketing, communications and invest
Via MarketBeat · September 27, 2026
A 64-year streak of increasing the payout makes this a top dividend stock.
Via The Motley Fool · September 27, 2026
Bristol Myers Squibb raised its 2026 sales outlook in July, while Novo Nordisk expects its sales to be flat at best this year, yet Bristol Myers Squibb trades at the lower earnings multiple.
Via The Motley Fool · September 27, 2026
Equillium (NASDAQ:EQ) Chief Scientific Officer Stephen Connelly outlined the company’s plans to advance its lead programs, including an oral aryl hydrocarbon receptor, or AhR, modulator for ulcerative colitis and an oral bispecific peptide for celiac disease, during a fireside chat.
Connelly said t
Via MarketBeat · September 27, 2026
This is one of the highest-quality businesses in the conglomerate's portfolio.
Via The Motley Fool · September 27, 2026
The cloud unit is growing faster than it has in years. Why are the shares cheaper than they were in August?
Via The Motley Fool · September 27, 2026
SpaceX is getting a lot of attention, but Nvidia is still the better buy.
Via The Motley Fool · September 27, 2026
Elon Musk has two of the largest companies in the world under his management.
Via The Motley Fool · September 27, 2026
AI's power bottleneck is creating two very different opportunities. See how GE Vernova and Bloom Energy compare in terms of growth, valuation, risk, and ability to power the data center boom.
Via The Motley Fool · September 27, 2026
Columbus McKinnon (NASDAQ:CMCO) CFO John Linker said the company is focused on executing its integration of Kito Crosby, delivering planned cost synergies and reducing debt following the transformative acquisition.
Linker, who joined the company July 1, told Sidoti conference attendees that the Kit
Via MarketBeat · September 27, 2026
Tamboran Resources (NYSE:TBN) said it has begun selling gas from the Beetaloo Basin into the Northern Territory market, marking a milestone for the company as it works to establish longer-term production performance and advance broader development plans.
Chief Executive Officer Todd Abbott said gas
Via MarketBeat · September 27, 2026
This pending purchase could result in both cost savings and supply chain advantages.
Via The Motley Fool · September 27, 2026
Muse is tantalizing investors.
Via The Motley Fool · September 27, 2026
The small coffee shop chain has big ambitions.
Via The Motley Fool · September 27, 2026
Nvidia and Apple generated nearly the same amount of revenue during their most recent quarters.
Via The Motley Fool · September 27, 2026
ThredUp (NASDAQ:TDUP) executives said the online resale company delivered a record second quarter across buyers, sellers, orders and revenue, while also navigating a recent shift toward more price-sensitive behavior among budget-conscious consumers.
Speaking at Wells Fargo’s consumer conference, Ch
Via MarketBeat · September 27, 2026
Interest rates are both a headwind and a tailwind for Ares Capital.
Via The Motley Fool · September 27, 2026
There's a good reason why XRP has never traded higher than a price of $3.84 in more than 14 years.
Via The Motley Fool · September 27, 2026
Nike has struggled to rebuild its brand, and a turnaround won't be quick or easy.
Via The Motley Fool · September 27, 2026
Four of the chipmaker's five previous best years since 1981 were followed by a down year. Why would 2027 be different?
Via The Motley Fool · September 27, 2026
The industry disruptor hasn't been a market-beating investment for its shareholders.
Via The Motley Fool · September 27, 2026
SpaceX is currently valued at roughly $2 trillion.
Via The Motley Fool · September 27, 2026
Palantir's growth is extraordinary, but the valuation sets a demanding bar. See what AIP, margins, government demand, and the math reveal about its long-term upside.
Via The Motley Fool · September 27, 2026
Nkarta (NASDAQ:NKTX) said it expects to present initial clinical data from its autoimmune disease programs at the American College of Rheumatology’s 2026 Convergence meeting in November, including presentations in myositis, scleroderma and program-wide safety.
The company is developing an allogenei
Via MarketBeat · September 27, 2026
Managing investments may not quite be the business you think it is.
Via The Motley Fool · September 27, 2026